In vivo and In vitro Drug Interactions Study of Glimepride with Atorvastatin and Rosuvastatin
2010

Study of Drug Interactions Between Glimepride and Statins

Sample size: 30 publication 10 minutes Evidence: moderate

Author Information

Author(s): V. J. Galani, M. Vyas

Primary Institution: A. R. College of Pharmacy and G. H. Patel Institute of Pharmacy

Hypothesis

The study aims to investigate the in vivo and in vitro drug interactions of glimepride with atorvastatin and rosuvastatin.

Conclusion

Glimepride metabolism is minimally affected by rosuvastatin, making it safer for coadministration, while atorvastatin significantly increases glimepride's bioavailability.

Supporting Evidence

  • Atorvastatin significantly increased the bioavailability of glimepride.
  • Rosuvastatin had minimal impact on glimepride metabolism in vitro.
  • Coadministration of atorvastatin resulted in a significant decrease in glimepride clearance.
  • The study used validated methods for pharmacokinetic analysis.
  • In vivo results showed a significant increase in AUC for glimepride when coadministered with atorvastatin.

Takeaway

This study looked at how two cholesterol-lowering medicines affect a diabetes medicine. One medicine is safe to take together, but the other can make the diabetes medicine work too strongly.

Methodology

The study involved in vitro testing using human liver microsomes and in vivo testing in Wistar rats, analyzing drug interactions through pharmacokinetic parameters.

Potential Biases

Potential bias in drug interaction assessment due to the use of animal models.

Limitations

The study was conducted on rats, which may not fully represent human responses.

Participant Demographics

Wistar rats of either sex, weighing 200-250 g.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.4103/0975-1483.63169

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication